Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee has granted equity awards to one new employee. The grants include options to purchase 5,550 shares of common stock at an exercise price of $11.07 per share, which matched the closing price on February 21, 2025. Additionally, the employee received restricted stock units to acquire 2,800 shares of common stock. These equity awards were issued under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 5,550 shares of the Company’s common stock at an exercise price per share of $11.07, which was the closing price on February 21, 2025, and restricted stock units to acquire a total of 2,800 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, A2a/A2b receptors, CD39 and AXL. For more information about Arcus Biosciences’s clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20250224574130/en/

Investor Inquiries:

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Maryam Bassiri

AD, Corporate Communications

(510) 406-8520

mbassiri@arcusbio.com

Source: Arcus Biosciences

FAQ

How many shares were granted in RCUS's February 2025 employee inducement awards?

The new employee was granted options to purchase 5,550 shares and restricted stock units to acquire 2,800 shares of Arcus Biosciences common stock.

What was the exercise price for RCUS's February 2025 stock options grant?

The stock options were granted at an exercise price of $11.07 per share, which was the closing price on February 21, 2025.

Under which plan were RCUS's February 2025 equity awards granted?

The equity awards were granted under Arcus Biosciences' 2020 Inducement Plan, approved under NYSE Listed Company Manual Rule 303A.08's inducement exception.

How many employees received RCUS's February 2025 inducement grants?

One new employee received the inducement grants from Arcus Biosciences.